DENDREON PHARMACEUTICALS LLC. Products & Brands

Products

Category

Product

Brand

Description

Global Market for Cell and Gene Therapy (BIO225B)

Provenge (sipuleucel-T)

Provenge (sipuleucel-T) is an immunotherapy product made from a patient’s own immune cells indicated for late-stage prostate cancer. It received FDA approval in 2010. It was withdrawn from the EU in 2015.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.